<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714060</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A228-HSV</org_study_id>
    <nct_id>NCT04714060</nct_id>
  </id_info>
  <brief_title>UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals</brief_title>
  <official_title>A Randomized, Single-blind, Dose-selected Phase II Trial to Evaluate the Safety and Efficacy of UB-621 in Adults With Recurrent Genital HSV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UBP Greater China (Shanghai) Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UBP Greater China (Shanghai) Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, single-blind, dose-selected phase II trial to evaluate the safety, efficacy and&#xD;
      PK of UB-621 in adults with recurrent genital HSV-2 infection&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with episodes before and after UB-621 treatment (self-comparison)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Proportion of subjects with episodes is calculated as the number of subjects with episodes divided by the number of total subjects. Primary endpoint is the self-comparison of proportion of subjects with episodes before and after UB-621 treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>Lesion rate is calculated as the number of days with lesion divided by the number of study days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of recurrent lesions</measure>
    <time_frame>16 weeks</time_frame>
    <description>Duration of recurrent lesions is calculated as consecutive days with lesions of HSV score 2-7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>Recurrence rate is defined as number of recurrences divided by the total number of study days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first recurrence of lesion</measure>
    <time_frame>16 weeks</time_frame>
    <description>Time to first recurrence of lesion as reported by patient and verified by investigator.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HSV-2 shedding rate.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Viral shedding rate is defined as the number of positive anogenital swabs divided by total number of swabs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical and Subclinical HSV-2 Shedding Rates</measure>
    <time_frame>8 weeks</time_frame>
    <description>Daily record of subject self-assessment of genital lesions in subject diary in addition to anogenital swabs collected daily from subjects during the follow-up periods will be used to evaluate the clinical (lesional) and subclinical (non-lesional) HSV-2 shedding rates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of HSV-2 Shedding Episodes</measure>
    <time_frame>8 weeks</time_frame>
    <description>The rate of HSV-2 shedding episodes is the number of onsets of shedding episodes divided by the total number of days with swabs collected. Shedding episodes are defined as consecutive HSV-2 positive swab results including no more than 1 consecutive negative result or missed swab. The episodes are preceded and followed by 2 consecutive negative swab results.</description>
  </other_outcome>
  <other_outcome>
    <measure>HSV-2 viral load</measure>
    <time_frame>8 weeks</time_frame>
    <description>Anogenital swab samples collected from subjects during follow-up period will be used to quantify HSV-2 DNA copies.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Recurrent Genital Herpes</condition>
  <arm_group>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg/kg UB-621 group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg UB-621 group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-621</intervention_name>
    <description>mAb by SC administration</description>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_label>cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be at least 18 years of age inclusive.&#xD;
&#xD;
          -  Subject must be HSV-2 seropositive&#xD;
&#xD;
          -  Subjects have a history of recurrent genital herpes in the past year&#xD;
&#xD;
          -  Subjects have a negative result on the HIV Ab/Ag assay&#xD;
&#xD;
          -  Subjects must agree to use contraception during study participation&#xD;
&#xD;
          -  Subjects must be willing to collect a swab each day from their genital area&#xD;
             (non-lesional as well as lesional, if appropriate) during the swabbing periods, which&#xD;
             are 8 weeks period after the administration of study drug.&#xD;
&#xD;
          -  Subject must be willing to go back to the hospital within 72 hours after the new&#xD;
             lesions are shown in the anal and genital area.&#xD;
&#xD;
          -  Subject must be willing to observe the syndromes around the anal and genital area&#xD;
             during study period, to evaluate the lesions according to the HSV lesion score, and to&#xD;
             record in the patient dairy&#xD;
&#xD;
          -  Female subjects must have a negative serum Î²-HCG at Screening and a negative urine&#xD;
             pregnancy test prior to study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious medical conditions, including poorly controlled diabetes, significant&#xD;
             autoimmune diseases, co-existing sexually transmitted disease presentation (except&#xD;
             HSV) in the anogenital area, etc. that may interfere with the assessment of the&#xD;
             efficacy of UB-621.&#xD;
&#xD;
          -  History or current evidence of malignancy except for a localized non-melanoma skin&#xD;
             cancer&#xD;
&#xD;
          -  Known immunosuppression&#xD;
&#xD;
          -  Exposure to HSV vaccine&#xD;
&#xD;
          -  Medical history of macular or maculopapular skin reactions to antibody (ie, as&#xD;
             evidenced by IgG or plasma administration)&#xD;
&#xD;
          -  Any other conditions that in the judgment of the Investigator would preclude&#xD;
             successful completion of the clinical study&#xD;
&#xD;
          -  Treatment with systemic steroids or other immunomodulating agents within 30 days prior&#xD;
             to Screening or planned treatment with systemic steroids or immunomodulators during&#xD;
             the study period.&#xD;
&#xD;
          -  Renal impairment and/or hepatic impairment&#xD;
&#xD;
          -  ECG abnormalities of clinical relevance or cardiovascular conditions&#xD;
&#xD;
          -  Abnormal blood tests according to &quot;Toxicity Grading Scale for Healthy Adult and&#xD;
             Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trial &quot;in the Guidance&#xD;
             for Industry, 2007:&#xD;
&#xD;
               1. albumin&lt;3 g/dl&#xD;
&#xD;
               2. ALP&gt;2.5*ULN&#xD;
&#xD;
               3. ALT&gt;2.5*ULN&#xD;
&#xD;
               4. AST&gt;2.5*ULN&#xD;
&#xD;
               5. Bilirubin&gt;1.5*ULN&#xD;
&#xD;
               6. CPK&gt;1.5*ULN&#xD;
&#xD;
               7. rGGT&gt;2.5*ULN&#xD;
&#xD;
               8. Hemoglobin: female&lt;11 g/dl; male&lt;12.5 g/dl&#xD;
&#xD;
               9. platelet&lt;125*10E3/ul&#xD;
&#xD;
              10. WBC&lt;2.5*10E3/ul or&#xD;
&#xD;
              11. ANC&lt;1.5*10E3/ul&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Linda Shih, DVM</last_name>
    <phone>+886 36684800</phone>
    <phone_ext>3851</phone_ext>
    <email>linda.shih@unitedbiopharma.com</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

